Medical Condition News

RSS

USC, Las Encinas Hospital to study on schizophrenia, bipolar disorder in younger, older adults

Schizophrenia and bipolar disorder affect 3% to 4% of the world's population, or about 222 million adults worldwide. In the United States, bipolar disorder affects about 5.7 million adult Americans 18 and older. Bipolar disorder, or manic depression, is a serious brain disorder that causes extreme shifts in mood, energy and functioning. People with the disorder experience episodes of mania and depression that can last from days to months. These symptoms usually begin in late adolescence, but can begin in early childhood or as late as a person's 40s or 50s. There is a strong genetic component related to bipolar disorder.

28 Sep 2010

Michael J. Fox Foundation launches PPMI clinical study to identify Parkinson's disease biomarkers

The Michael J. Fox Foundation has launched the Parkinson's Progression Markers Initiative (PPMI), the first ever large scale clinical study exclusively focused on identifying and validating Parkinson's disease biomarkers.

28 Sep 2010

Genomics obtains worldwide rights to The Garvan Institute of Medical Research's methylation DNA biomarkers

Clinical Genomics Pty. Ltd (Sydney, Australia) and The Garvan Institute of Medical Research (Sydney, Australia) today announced that they have entered into a license agreement in relation to novel biomarkers discovered by scientists at the Garvan Institute. Under the terms of the agreement, Clinical Genomics obtains worldwide exclusive rights to the Garvan's proprietary cancer associated methylation DNA biomarkers for the diagnosis and or treatment of colorectal cancer.

28 Sep 2010

DecImmune Therapeutics receives funds to improve ischemia reperfusion injury outcomes

DecImmune Therapeutics announced today that it has received a $1 million equity investment from Astellas Venture Management and has additionally been awarded $2.2 million in Phase II SBIR funding from the National Institutes of Health.

28 Sep 2010

Guided Therapeutics files PMA for LightTouch Cervical Scanner

Guided Therapeutics, Inc. announced that it filed its completed premarket approval application (PMA) for the LightTouch Cervical Scanner with the U.S. Food and Drug Administration (FDA) for patients at risk for cervical cancer.

28 Sep 2010

Celiac disease on the rise in adults: Study

According to a new study published Monday in the Annals of Medicine, cases of intestinal disorder known as Celiac disease are on the rise with many adults developing the disease.

28 Sep 2010

Scientists find Alzheimer's Disease reduces human brain cancer growth

Scientists at the Roskamp Institute in Sarasota, Florida, have shown that mice that naturally develop Alzheimer's are able to ward off the growth of brain cancer. In a series of experiments published in the Journal of Neuroscience, they showed that mice that spontaneously develop Alzheimer's Disease are able to dramatically reduce the growth of a human brain cancer.

28 Sep 2010

Study finds acupuncture is not effective in stroke recovery

Acupuncture does not appear to aid in stroke recovery, according to a new study published in CMAJ. This study, perhaps the most comprehensive to date as it includes trials published in English language and Asian journals, was a systematic review conducted by researchers in South Korea and the United Kingdom.

28 Sep 2010

KeyVive provides Simplatype mHealth SMS technology to improve healthcare

KeyVive, Inc., a healthcare technology company that uses social media and self management tools to help individuals with chronic illnesses, is dialing up a ground-breaking, HIPAA compliant mHealth technology for people not only affected by diabetes, but also with other diseases.

28 Sep 2010

Rockland receives Phase I SBIR grant to develop assay for monitoring Akt pathway activity

Rockland Immunochemicals Inc., a biotechnology company focusing on antibodies and antibody based tools for basic research, assay development and preclinical studies, today announced that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop a pharmacodynamic assay to monitor the Akt/mTOR signaling pathway.

28 Sep 2010

Amira submits IND application for AM152 antagonist

Amira Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for AM152, a novel LPA1 antagonist. If accepted, the IND will enable Amira to begin Phase 1 safety studies with the compound in healthy subjects.

28 Sep 2010

BCBC awards $5 million for cell therapy research in type 1 diabetes

Maike Sander, MD, associate professor of pediatrics and cellular & molecular medicine at the University of California, San Diego School of Medicine has been awarded nearly $5 million by the Beta Cell Biology Consortium (BCBC) to lead an interdisciplinary team in cell therapy research for type 1 diabetes.

28 Sep 2010

KAI Pharmaceuticals enrolls patients in Phase 1b study of KAI-4169 for treatment of SHPT

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of the first patients in a Phase 1b study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of secondary hyperparathyroidism, which is a frequent and serious complication of end-stage renal disease.

27 Sep 2010

Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients

Chelsea Therapeutics International, Ltd. has initiated enrollment in a multinational, 12-week, double-blind Phase II trial designed to compare the efficacy and tolerability of CH-4051 against methotrexate (MTX) in 250 patients with rheumatoid arthritis (RA) who are experiencing an inadequate response to MTX treatment.

27 Sep 2010

REMURA Phase 2 clinical study results highlighted at Tear Film & Ocular Surface conference

ISTA Pharmaceuticals, Inc. today highlighted results from the Company's REMURA (bromfenac ophthalmic solution for dry eye) Phase 2 clinical study.

27 Sep 2010

S*BIO initiates SB939 Phase 2 clinical trial for metastatic prostate cancer

S*BIO Pte Ltd today announced the initiation of a Phase 2 clinical trial of SB939, its novel orally-active HDAC inhibitor, in patients with recurrent or metastatic prostate cancer (HRPC).

27 Sep 2010

European Society of Cardiology to support EuroPRevent Meeting

Workplace wellness programmes play a vital role in preventing cardiovascular disease and stroke. This year's World Heart Day theme is to encourage employers and employees to take simple steps to improve heart-health in the workplace. The European Society of Cardiology is keen to support this theme, which coincides with the upcoming launch of two major initiatives at the next EuroPRevent Meeting in April 2011 in Geneva.

27 Sep 2010

Study finds increasing number of elderly people are prone to celiac diseases

Working to solve the puzzle of when people develop celiac disease has led researchers from the University of Maryland School of Medicine Center for Celiac Research to some surprising findings. They have found that the autoimmune disorder is on the rise with evidence of increasing cases in the elderly.

27 Sep 2010

TONES procedure is safe and effective for treating brain diseases, traumatic injuries

Surgeons at the University of California, San Diego, School of Medicine and University of Washington Medical Center have determined that transorbital neuroendoscopic surgery is a safe and effective option for treating a variety of advanced brain diseases and traumatic injuries. This groundbreaking minimally invasive surgery is performed through the eye socket, thus eliminating the removal of the top of the skull to access the brain.

27 Sep 2010

MediciNova receives FDA approval to proceed with initial trial of ibudilast

MediciNova Inc, a biopharmaceutical company publicly traded on the NASDAQ Global Market and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today reported FDA's approval to proceed with an initial trial of the company's neurological drug candidate, ibudilast (MN-166/AV411), as a potential new pharmacotherapy for methamphetamine addiction.

27 Sep 2010

Medical Condition News

USC, Las Encinas Hospital to study on schizophrenia, bipolar disorder in younger, older adults

Michael J. Fox Foundation launches PPMI clinical study to identify Parkinson's disease biomarkers

Genomics obtains worldwide rights to The Garvan Institute of Medical Research's methylation DNA biomarkers

DecImmune Therapeutics receives funds to improve ischemia reperfusion injury outcomes

Guided Therapeutics files PMA for LightTouch Cervical Scanner

Celiac disease on the rise in adults: Study

Scientists find Alzheimer's Disease reduces human brain cancer growth

Study finds acupuncture is not effective in stroke recovery

KeyVive provides Simplatype mHealth SMS technology to improve healthcare

Rockland receives Phase I SBIR grant to develop assay for monitoring Akt pathway activity

Amira submits IND application for AM152 antagonist

BCBC awards $5 million for cell therapy research in type 1 diabetes

KAI Pharmaceuticals enrolls patients in Phase 1b study of KAI-4169 for treatment of SHPT

Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients

REMURA Phase 2 clinical study results highlighted at Tear Film & Ocular Surface conference

S*BIO initiates SB939 Phase 2 clinical trial for metastatic prostate cancer

European Society of Cardiology to support EuroPRevent Meeting

Study finds increasing number of elderly people are prone to celiac diseases

TONES procedure is safe and effective for treating brain diseases, traumatic injuries

MediciNova receives FDA approval to proceed with initial trial of ibudilast

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Latest News